SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BDTX

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.31-$0.08 (-5.76%)
 
Market cap
$75.3M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 31, 2020
Market Cap$75.28M-66.0%
Revenue (ttm)$0-100.0%
Net Income-$44.07M-305.0%
EPS-$0.76-311.1%
Shares Out57.47M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume673,414
Open$1.33
Previous Close$1.39
Day's Range$1.31 - $1.40
52-Week Range$1.31 - $3.97
Beta3.46
AnalystsBuy
Price Target$8.00(+510.69%)
Earnings DateMar 15, 2027

About BDTX

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Address
245 First Street, Cambridge, MA, 02142, US
Market Cap
75 million
Employees
21
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $8.00 (+469.4%)

1 firm rating BDTX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From BDTX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-5.76%
5 Days
-10.27%
1 Month
-37.02%
6 Months
-42.54%
1 Year
-65.97%

$BDTX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BDTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BDTX's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BDTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BDTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BDTX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BDTX

VTIVanguard Morningstar Total Stock Market ETF$2.05M
IWMiShares Russell 2000 ETF$1.63M
VXFVanguard Extended Market ETF$1.07M
FESMFidelity Enhanced Small Cap ETF$920.52K
DFSVU.S. Small Cap Value Portfolio ETF Class Shares$751.87K
SMLFiShares U.S. Small-Cap Equity Factor ETF$672.81K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BDTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Positive Phase 2 results and FDA feedback supporting registration pathway for lead drug silevertinib outweigh routine conference participation announcements.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.18%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.12%
STSBiShares Factors US Small Blend Style ETF0.07%
BSVOEA Bridgeway Omni Small-Cap Value ETF0.02%
IBBQInvesco Nasdaq Biotechnology ETF0.01%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.00%

Weight is the stock’s share of each fund’s holdings.